


21st Anglonordic Life Science Conference
COUNTY HALL, LONDON, 3 APRIL 2025

ANGLO NORDIC



CONFERENCE BROCHURE

Tap for more

Contents

Tap an item to view

[Venue Map](#)



[Introduction](#)



[Our Sponsors](#)



[Programme](#)



[Speakers](#)



[Technology Room Presenters: Morning](#)



[Biotech Room 1 Presenters: Morning](#)



[Biotech Room 2 Presenters: Morning](#)



[Technology Room Presenters: Afternoon](#)



[Biotech Room 1 Presenters: Afternoon](#)



[Biotech Room 2 Presenters: Afternoon](#)



[Delegations](#)



[Charity of the Year](#)



[Attending Investors](#)




[Attending Companies and Organisations](#)



Back to Contents



ANGLO NORDIC



Dear Delegate,

I am delighted to welcome you to the 21st annual Anglonordic Life Science Conference in London!

When I started the conference more than 20 years ago, I could not have imagined the challenges it would see, from the economic crash of 2008, raising serious questions about venture funding in Europe, through the eruption of Eyjafjallajökull in 2010 that stranded our Nordic delegates in London, to the Covid pandemic that postponed the 2020 conference, forcing a switch to digital in 2021 and 2022.

In 2018, Anglonordic moved to its current venue, the prestigious and historic County Hall. At this time we also reorganised the conference leadership with M Ventures as chair under Hakan Goker, supported by Optimum Strategic Communications as programme director and long-term partner BioPartner UK as conference organiser. This powerful committee has positioned Anglonordic as a beacon in the Life Sciences investor conference calendar, this year attracting 90 investment firms and over 350 attendees from 20 different countries.

On behalf of the Organising Committee and Conference Team, I hope you all benefit from the insights, networking and partnerships on offer today.

Mattias Johansson

Founder,

Anglonordic Life Science Conference



Our Sponsors

FOUNDING SPONSOR



SILVER SPONSOR



RECEPTION SPONSOR



AFTERNOON DRINKS SPONSOR




SUPPORTING SPONSORS



MEDIA PARTNERS



[Back to Contents](#)



MM ventures

A leading global
strategic corporate VC
investing in visionary
Biotechnology and
Technology companies

[Back to Contents](#)



INTERNATIONAL STRATEGIC COMMUNICATIONS USING OUR MULTI-CHANNEL APPROACH

For Life Sciences, Healthcare & Industrial Biotechnology

- ✓ **Fundraising**
- ✓ **Business development**
- ✓ **Deal making**
- ✓ **M&A**
- ✓ **IPO**
- ✓ **Crisis communications**
- ✓ **Profile raising**
- ✓ **Maximising data**



Visit Optimum's newsroom

featuring Optimum TV, podcasts and
insights from leaders in life sciences



Optimumcomms.com



[@optimum-strategic-communications](https://www.linkedin.com/company/optimum-strategic-communications)

London



Amsterdam



New York



San Diego



San Francisco



Zurich



Stockholm



Programme

All programme items will take place in Biotech Room 1 unless otherwise stated

08:00 – 08:45 Registration

08:45 – 08:50 Welcome

Mary Clark, CEO, Optimum Strategic Communications

Hakan Goker, *Managing Director, M Ventures*

Mattias Johansson, *CEO, Ezenze Limited*

08:50 – 09:15 Keynote

Göran Ando MD, *Chairman, Nouscom AG*

09:15 – 10:00 Panel: What's Next in Immunology

Chair:

Eleanor Malone, *Editor-in-Chief, Commercial Insights, Citeline*

Panelists:

Mark Bodmer, *CEO, Nucleome Therapeutics*

Samuel Black, *Director Business Development & Licensing, Merck KGaA*

Phil L'Huillier, *CEO, Scancell*

Marina Udier, *CEO, Nouscom AG*

10:00 – 10:30 Coffee Break

[Back to Contents](#)



Programme

10:30 – 11:45 Pitch Presentations

Bioconvergence	More in Drug Development	CNS - Novel Approaches
<i>Technology Room</i> Moderated by Oliver Hardick, M Ventures Polyceutix Oncoinvent Tenaces BioSciences Pictura Bio Minos Biosciences HHC Medical	<i>Biotech Room 1</i> Moderated by Hollie Vile, Optimum Strategic Communications Neobe Therapeutics Synklino MicroA Nucleome Therapeutics Infinitopes Outrun Therapeutics	<i>Biotech Room 2</i> Moderated by Noga Yerushalmi, M Ventures ReSynapse Therapeutics Vesper Bio Origenis Kesmalea Therapeutics Lario Therapeutics Akasi Pharma

11:45 – 12:45 Investors' Panel - Trends in Life Science Investments

Chair:

Stephen Hansen, *Director of Biopharma Intelligence, BioCentury*

Panelists:

Hakan Goker, *Managing Director, M Ventures*


Allan Marchington, *Head of Life Sciences, ICG*

Lucy Edwardes Jones, *Life Science Investor, BGF Investment Management*

Erica Whittaker, *VP, Head of Corporate Venture Fund, UCB*

12:45 – 13:45 Networking Lunch

[Back to Contents](#)



Programme

13:45 – 14:45 Panel: Women's Health

Chair:

Lisa Urquhart, *Life Science Journalist*

Panelists:

Colleen Acosta, *CEO, Freya Biosciences*

Sebastian Bohl, *VP, Global Head New Product Planning and Business Excellence, Healthcare Business of Merck*

Casper Johansen, *VP and Head of External Innovation & Scientific Licensing, Ferring Pharmaceuticals*


Ksenija Pavletic, *Partner, Jeito Capital*

Sara Secall, *General Partner, Inveready*

14:45 – 16:00 Pitch Presentations

Novel Tech Solutions for Life Sciences	More in Drug Development	New Modalities and Administration Methods
<i>Technology Room</i> Moderated by Eva Haas, Optimum Strategic Communications	<i>Biotech Room 1</i> Moderated by Nadiya Ishnazarova, M Ventures	<i>Biotech Room 2</i> Moderated by Stephen Adams, Optimum Strategic Communications
Astraveus iotaSciences G.CLIPS Biotech Curve Therapeutics LightOx Yaqrit	Proxi Biotech Resolution Therapeutics U-Ploid Biotechnologies BiPER Therapeutics Mabylon AG Walther Therapeutics	Bioarchitech Scarlet Therapeutics Blue Cell Therapeutics ReNewVax Cymab Aptadel Therapeutics

[Back to Contents](#)



Programme

16:00 – 16:30 Coffee Break

16:30 – 17:30 If I Knew Then What I Know Today

Chair:

Mike Ward, *Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate*

Panelists:

Peter Haahr, *CEO, LEO Foundation*

Joern-Peter Halle, *Venture Partner and Advisor, BGV*

Sean Marett CMG, *Managing Director, Marett Consulting*

Ruth McKernan, *Operating Partner, SV Health Investors*

17:35 – 17:40 Charity of the Year: Cure Parkinson's

Helen Matthews, *CEO*


17:40 – 17:45 Conclusions

17:45 – 18:45 Afternoon Drinks Reception

Hosted by



[Back to Contents](#)



Speakers

Introduction and Conclusions

Mary Clark

Founder & CEO


Optimum Strategic Communications



Mary has a 25-year successful track record in providing strategic corporate and financial communications to both early- and late-stage healthcare companies and has worked with over 400 biotech and healthcare clients across Europe and the US. She has developed several high-profile investor focused campaigns and has been instrumental in strategic positioning ahead of fundraising rounds of private financings, IPOs and follow-on public financings.

She founded Optimum in 2017 with the mission to provide the best strategic communications advice and implement effective communications programmes to achieve high impact results. Prior to this, Mary built and led healthcare businesses at several international PR&IR agencies. She started her career at BTG plc where she was involved in the Company's IPO and the start-up of several new tech and biotech companies.

[Back to Contents](#)



Hakan Goker

Managing Director

M Ventures



Hakan Goker, PhD, heads the Biotechnology Investments covering Healthcare and Life Sciences. He joined M Ventures in 2013 and has been investing in the sector for 18 years. Previously, Hakan was a partner at Aescap Venture investing in European opportunities. Hakan started his investment career at Atlas Venture focusing on global investment opportunities in healthcare and medical technologies across US, Europe and Asia. He was instrumental in the creation and financing, business and R&D strategies of multiple companies while at Aescap and Atlas. Hakan continues his active investing role and represents M Ventures on multiple portfolio companies. He comes from an academic background receiving his Ph.D. in oncology from the Institute of Cancer Research/ University of London, UK and continuing his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his B.Sc. Hons, from University College London.



Mattias Johansson

CEO , Ezenze and
Founder, Anglonordic Life Science
Conference



Mattias Johansson founded the Anglonordic Life Science Conference in 2004 to facilitate and encourage communication across the investor and R&D communities of the UK and Scandinavia. He has over 20 years' experience in the Life Science industry with focus on partnering and investment. Today Mattias is Director and Founder of Ezenze, a management consultancy in Sweden, with a focus on marketing and sponsorship management.


Keynote

Göran Ando MD

Chairman
Nouscom AG



Dr. Ando brings 45 years of experience as one of the most experienced and respected leaders in the global pharmaceutical



industry. Dr. Ando is the retired Chair of the Board of Novo Nordisk A/S, a global pharmaceutical company with \$120 billion market capitalization and is the current Chairman of EyePoint Pharmaceuticals (USA), Nouscom (Switzerland) and Nanexa AB (Sweden).


Dr. Ando's career began in the pharmaceutical industry in 1978 as Medical Director of Pfizer AB, progressing to Director, Clinical Research with Pfizer International in the US. He then became VP, Medical and Scientific Affairs at Bristol-Myers, returning to Sweden as President of the Astra Research Centre. Between 1989 and 1995, he held various senior appointments at Glaxo, including R&D Director for Glaxo Group Research.

Dr. Ando joined Pharmacia AB in 1995 as EVP and Deputy CEO, moving to the U.S. in 1997 to lead R&D with additional responsibilities for manufacturing, information technology, business development and M&A. During his eight-year tenure as Head of R&D at Pharmacia/Pharmacia & Upjohn, 17 new drugs were approved by the U.S. Food & Drug Administration prior to Pharmacia's acquisition by Pfizer for \$60 billion.

Dr. Ando was then appointed CEO of Celltech Group PLC in the United Kingdom, one of the most successful European biotech companies, until it was acquired by UCB Pharma for \$3 billion in 2005.

Dr. Ando received his Bachelor of Arts degree from Uppsala University in Sweden and Doctor of Medicine degree from Linköping University in Sweden.

[Back to Contents](#)



Panel: What's Next in Immunology?


Eleanor Malone (chair)

Editor-in-Chief, Commercial Insights
Citeline



Eleanor directs editorial content produced by the Commercial Pharma Insights team (Scrip, Generics Bulletin and In Vivo) in the US and Europe, liaising closely with counterparts in policy and regulatory coverage and in Asia. She oversees and contributes to daily analytical content based on biopharma industry developments and trends, interviewing key experts and industry leaders. Eleanor joined Citeline predecessor Informa in 2000 as companies reporter on Scrip, and has held a number of editorial roles on Pharma Intelligence's pharma and medtech publications. She has interviewed countless industry leaders and specialists, explored business developments and strategy, pipeline trends, policy and regulatory stories, delved into M&A, licensing, partnerships, financing, financial reports, clinical trial updates, market trends and more. She regularly appears on conference panels and in the media to discuss matters relating to the biopharma industry. She has an MA in modern languages from the University of Edinburgh and previously worked as a translator of European business news for the Financial Times.

[Back to Contents](#)




Samuel Black

Director Business Development &
Licensing
Merck KGaA



Sam Black is a Business Development & Licensing professional at Merck with 7+ years of pharma/biotech experience in Europe, APAC and the US. He has executed numerous transactions, leading international, cross-functional, project teams on negotiations primarily across oncology, immuno-oncology, neurology and immunology. He has broad experience across deal types and structures (e.g. in and out-licensing of assets and technologies, collaboration agreements and option agreements, asset acquisition, academic partnerships, combination agreements, and companion diagnostic agreements) including corporate components of such transactions (e.g.: equity considerations), up to deal values of €1B+.

Sam gained a MPhil in Bioscience Enterprise from the University of Cambridge and a MEng in Biochemical Engineering with Management from University College London.



Mark Bodmer

CEO

Nucleome Therapeutics



Following a PhD in genetics at the University of Cambridge, Mark joined Celltech in the UK in the early 1980s, starting a career in the emerging field of biotech which has led to six approved products currently on the market. Mark has held multiple biotech CEO and CSO roles and worked in big pharma research leadership and BD across the US, Europe and the UK. This has provided broad experience in drug discovery and development, particularly biologics, company-founding and building, financing, and deal-making.

Phil L'Hullier


CEO

Scancell



Phil brings a wealth of leadership experience in the biotechnology and pharmaceutical sectors, with a proven track record of driving growth and innovation. Before joining Scancell, he served as CEO of CatalYm GmbH, a cancer immunotherapy company, where he significantly

[Back to Contents](#)



enhanced the company's visibility and investor base. Under his leadership, CatalYm secured over \$200 million in successful financing and advanced its lead program from Phase 1 to randomized Phase 2b clinical trials.

Previously, Phil led Merck Sharp & Dohme's (MSD) European Innovation Hub & Business Development, where he headed a team that successfully completed a number of acquisitions and partnerships. Prior to MSD, he served as Executive Director of Cancer Research Technology Ltd (CRT). He has also been instrumental in the formation of multiple companies and has held Non-Executive Director roles at Achilles Therapeutics, Artios Pharma, Blink Therapeutics, PsiOxus Therapeutics and others. Phil holds a PhD in biology and an MBA.

Marina Udier

CEO

Nouscom AG

During her 5-year tenure as the CEO of Nouscom, Marina Udier has led the company through first IND approval and subsequent multiple successful regulatory submissions in US and Europe, a licensing deal (with JnJ), and most recently a successful close of an oversubscribed series C financing (\$97M).



Prior to Nouscom, Marina was an operating Principal with Versant Ventures. Prior to Versant, Marina spent 7 years with Novartis Pharma in senior development and commercial roles in oncology and neuroscience. Marina's professional career started at McKinsey & Company healthcare practice in Chicago, where she worked with Fortune 500 companies in marketing, strategy and pricing. Marina received her PhD in Chemistry from Yale University. She authored peer reviewed publications covering HIV/AIDS research.

Investors Panel - Trends in Life Science Investments


Stephen Hansen (chair)

Director of BioPharma Intelligence
BioCentury



Stephen is BioCentury's Director of BioPharma Intelligence in the U.K., where he serves as one of the company's primary points of contact with European companies and investors. Stephen has covered clinical development, corporate strategy and finance in Europe, the U.S. and China for BioCentury for over a decade and is a frequent contributor to BioCentury's quarterly Financial Markets Preview and annual Buyside View and European Finance reports. He holds B.A.s in Biology and History from Bethel University and an M.Phil. in History from Oxford University.

[Back to Contents](#)



Lucy Edwardes Jones

Life Science Investor

BGF Investment Management



Lucy is an investor at BGF, the most active equity investor in the UK and Ireland with a balance sheet of £2.5bn. Lucy focuses on investments in the life sciences space, with a particular interest in drug discovery platforms. Her main role is to source and execute new investments, as well as supporting a number of investee companies at board level (currently Maxion Therapeutics, ViaNautis Bio, NanoSyrinx, Dunad Therapeutics, Theolytics). Prior to BGF, Lucy spent five years in strategy consulting at CIL where she focused on the healthcare and pharma sectors.

Allan Marchington

Managing Director, Head of Life

Sciences


ICG



Allan is Managing Director, and Head of Life Sciences, responsible for the Life Science Fund strategy and team at ICG.

Prior to ICG, Allan was Founder and Managing Partner of Bridge Valley Ventures, a successful life science investor, and prior to this

[Back to Contents](#)



was a Partner and Founder of Apposite Capital. Before this Allan was at Abingworth.

Formerly a PhD medicinal chemist at Pfizer, he later founded and was CEO of his own life sciences company before it was successfully acquired by Millennium Pharmaceuticals Inc. in 2000 where he became SVP Technology. On his return to the UK in 2003 Allan joined Abingworth to begin his investment career.


Erica Whittaker

VP, Head of Corporate Venture Fund
UCB Ventures



Erica is Vice President & Head of UCB Ventures, an evergreen strategic corporate venture fund which was set up in 2017 to invest in innovative, early stage therapeutic opportunities beyond UCB's current focus areas. She is on the Board of Directors of six UCB Ventures portfolio companies: Rinri Therapeutics, ExeVir, Neurona, EsoBiotec, Splice Bio, and Iris Medicine. Prior to joining UCB, Erica spent 10 years as a top-ranked biotechnology equity analyst for Merrill Lynch in London (1999-2009). Erica received BA degrees in Biology and in Comparative Literature from Brown University (Rhode Island USA). She obtained a PhD in Molecular Biology from the University of Edinburgh, and later an MBA from Heriot-Watt University Business School in Edinburgh.

[Back to Contents](#)



Panel: Women's Health

Lisa Urquhart (Chair)

Life Science Journalist

An award-winning journalist with more than 20 years' experience of covering the life sciences sector.

Lisa has held a number of roles including editor of Evaluate Vantage and biotechnology correspondent for the Financial Times. Her interests within biopharma include M&A and venture financing, alongside exploring health inequalities.



Colleen Acosta

CEO

Freya Biosciences

Colleen Acosta is the Founder and CEO of Freya Biosciences, a clinical-stage biotech company with headquarters in Copenhagen, Denmark and Boston, Massachusetts dedicated to developing microbial immunotherapies for high unmet medical needs in women's health. Freya has raised Series A funding of around \$50m to address immune drivers underlying a range of reproductive health conditions to create a future where everyone is empowered with optimal reproductive health.



[Back to Contents](#)



Sebastian Bohl

VP, Global Head New Product Planning
and Business Excellence
Merck Healthcare KGaA



Sebastian Bohl, PhD, leads New Product Planning & Business Excellence Fertility at Merck Healthcare KGaA, Darmstadt, Germany. Sebastian is a distinguished professional with a proven track record of driving strategic initiatives and delivering exceptional results. His extensive experience in international business environments, coupled with his expertise in the pharmaceutical, diagnostic, and medical device industries, makes him a respected leader in his field.

Prior to his current role, he served as the Lead Digital and Data Fertility, where he led the digital and data strategy for Fertility. Before that, he held the position of Vice President, Global Head New Business, developed new business opportunities, and led the transformation of the LabTech business. Sebastian's career at Merck also includes the roles in Strategic Marketing, Business Development and Strategic Planning.

Sebastian Bohl, PhD, has a strong educational background in biology, computer science and economics, with international experience in Germany, Switzerland, Sweden and USA.



Casper Johansen

VP and Head of External Innovation &
Scientific Licensing
Ferring Pharmaceuticals




Casper Johansen joined Ferring in 2011 and after roles in Canada, UK and Switzerland returned to Denmark in 2021 to head up the External Innovation and Scientific Licensing department. Casper holds a Master from University of Copenhagen in Pharmaceuticals Sciences.

Ksenija Pavletic

Partner
Jeito Capital



Ksenija Pavletic is a partner at Jeito Capital and a member of the founding team, with over 25 years' experience in pharma & biotech. She is an expert in both investment strategies and healthcare companies scaleups with a successful track record in fund raising, M&A, company & teams build ups, commercial organization build ups, product launches, market access.



Ksenija is also serving as an acting CEO of Jeito's portfolio company Advesya, a pioneering biopharma company for difficult-to-treat cancers.

Prior to joining Jeito, she was CEO of Swiss-based, reproductive health pharma company PregLem SA where she led the company's rapid expansion all the way to the commercial stage including its successful exit for CHF445 million three years after the inception. Prior to PregLem, Ksenija worked for eleven years with Serono (then Merck Serono) in various regional and global business, sales and marketing positions. Ksenija is also a member of W.I.T.H. (Women Innovating Together in Healthcare).

Panel: If I Knew Then What I Know Today

Mike Ward (Chair)

Global Head of Life Sciences &
Healthcare Thought Leadership
Clarivate



Mike Ward returns to pose questions to Anglonordic's retrospective panel for the 15th year running. As both a journalist and analyst, Mike has been writing award-winning analysis and comment on the life sciences industry for more than 35 years, and has held editorial and content leadership roles at various publications and organizations across the industry.

[Back to Contents](#)



Peter Haahr

CEO

LEO Foundation



At the LEO Foundation, Peter Haahr is leading one of Denmark's largest commercial foundations while developing efforts within philanthropic grant-giving and asset management. His prior experience includes positions as CFO of Novo Holdings, Denmark, and various leadership positions in Novo Nordisk A/S, both in headquarters and abroad. He has a master's degree in Finance & Accounting from Aarhus School of Business in Denmark.

Joern-Peter Halle

Venture Partner and Advisor

BGV



Peter is a self-employed advisor who works with clients along the value chain of the biopharmaceutical industry. He is a Venture Partner at BGV, a Senior Advisor at A.T. Kearney, chairs the SAB at Avidicure B.V., is advising individual biotech start-up companies, and is member of the supervisory board of Merck Healthcare KGaA. He co-created M ventures, Merck KGaA's corporate VC, and was chair of its Healthcare Investment Committee.

[Back to Contents](#)



He was most recently Chief Strategy Officer at Merck KGaA's Healthcare business where he led the functions for Strategy Development & Realization, Business Development, Data & IT, and Global Health & Bioethics.

Peter received his Ph.D. (Dr. rer. nat.) in molecular biology from the University of Konstanz in 1994. As a post-doc at the Gene Center Munich, he co-founded a start-up company focusing on R&D in dermatology where he was responsible for IP, bioinformatics, and technology development and served as Chief Business Officer. He joined Merck KGaA in 2005 as a member of the M&A/BD team and move to the Healthcare division after major contributions to the acquisition and integration of Serono. At Merck Healthcare, he held positions with increasing responsibilities ranging from Head of External Innovation, member of the Therapeutic Area Leadership Team Oncology, Head of Immuno-Oncology Research, to Global Head of Research.

Sean Marett CMG

Managing Director

Marett Consulting

Sean Marett is the outgoing Chief Business and Commercial Officer of BioNTech, where his services to the development of one of the Covid 19 vaccines resulted in a Royal Appointment to the Order of Saint Michael and Saint George.



[Back to Contents](#)



Prior to BioNTech, he worked in global strategic and regional marketing and sales roles at GlaxoSmithKline in the United States and Pfizer in Europe, before taking business development executive roles at Evotec and Lorantis. He has successfully executed complex licensing transactions with large pharmaceutical companies, negotiated M&A transactions and raised finance from investors. Marett built and ran a contract clinical manufacturing organization with operations across Europe and the United States for over half a decade for the contract manufacturer NextPharma. Marett has been Chairman of PHMR Ltd, a company specializing in market access and pharmaceutical reimbursement, since 2017. He previously held non-executive directorship of KWS BioTest and was a member of the investment committee of Mann BioInvest. He holds a BSc (Hons) in Biochemistry from Kings College London and an MBA from Manchester Business School.

Ruth McKernan CBE


Operating Partner
SV Health Investors

Ruth joined SV in 2018 as a Venture Partner. She has co-founded a number of SV companies AstronauTx, LoAus23 and Cumulus SV companies:

AstronauTx, LoAus23 and Cumulus alongside the Dementia Discovery Fund as well as Alchemab.




[Back to Contents](#)



Ruth has over 25 years in the pharma industry having held roles at Merck and Pfizer, leading several Research Sites in the UK and US. She has set up new Research Units, including Pfizer Regenerative Medicine and Neusentis, initiated multiple neuroscience partnerships, acquisitions and spinouts and played an active role in taking more than 10 compounds into the clinic. Immediately prior to joining SV, Ruth spent three years as Chief Executive Officer of the UK Government's Innovation agency, InnovateUK, supporting the UK's Industrial Strategy with responsibility for investing an annual budget of £1bn into Technology centres and SMEs.

Outside of SV, Ruth is a Trustee for Alzheimer's Research UK and previously served as Chair of the UK's BioIndustry Association. She is an enthusiast for innovation and entrepreneurship, sitting on multiple innovation and translation boards including the Academy of Engineering and the Francis Crick Institute. Ruth was made a Commander of the British Empire for services to business and innovation in 2013 and elected a Fellow of the Academy of Medical Sciences in 2015. In her spare time Ruth is an award winning science writer, avid gardener and spokesperson for Women in Innovation.

Ruth Has a BSc in Pharmacology and Biochemistry, a PhD in neuroscience and Honorary DSc from two Universities.



Charity of the Year: Cure Parkinson's

Helen Matthews

CEO

Cure Parkinson's



Helen has been a driving force behind the Cure Parkinson's charity since it was formed over 17 years ago, and has been instrumental in progressing some of the most promising and valuable research into finding a cure. Helen is well-known and highly engaged with the Parkinson's community, and brings a wealth of experience and knowledge to the helm.

[Back to Contents](#)




Technology Room Pitches

Morning

Theme: Bioconvergence

Moderator: Oliver Hardick, M Ventures




Presenter: Mads Holmegaard Sørensen, Co-Founder

At Polyceutix we are developing an innovative approach to cancer immunotherapy utilizing the unique antigen-presenting properties of nanodiscs.

We are a spinout from Stanford and DTU, currently incubated at the BioInnovation Institute.

[Back to Contents](#)





Presenter: Oystein Soug, CEO

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin in a clinical development program in two indications. Currently two phase 1/2a trials and one randomized phase 2 trial are ongoing in the US, UK and Europe. More than 150 patients with peritoneal carcinomatosis, secondary to ovarian and colorectal cancer, will be enrolled in the current program. Preliminary clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 30 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo (ONCIN:OL)

[Back to Contents](#)





ten**Aces**

molecular glue discovery

Presenter: Arnout Schepers

Tenaces Biosciences is focused on rational design of molecular glues for targeted protein degradation, using a data centric approach and machine learning. Our computational workflow will enable the targeting of new proteins, and will significantly reduce the time and cost of molecular glue development. We will develop a pipeline of proprietary molecular glues and bring these assets to market through strategic collaborations & out-licensing deals with pharma companies.



Pictura Bio

Presenter: Alex Batchelor, CEO

Pictura Bio is developing a one-minute, universal, pathogen diagnostic device that uses machine learning algorithms to identify specific infectious disease directly within patient samples at the point of care.

[Back to Contents](#)





Presenter: Pierre Le Ber, CEO


A spin-off from the ESPCI Paris - PSL University, Minos Biosciences is a deep tech, bio tools company aiming at generating unique datasets to revolutionise our understanding and treatment of complex diseases such as cancer, infectious and autoimmune diseases. The MinoSuite™ first-in-class, integrated cell analysis platform opens a new world of possibilities from fundamental discovery to drug development and precision medicine.

Minos was born in 2020, out of the PhD works and entrepreneurial spirit of Hubert Geisler and Gaël Blivet-Bailly, meeting with the in-depth scientific and clinical expertise of Profs Andrew Griffiths (co-inventor of phage display –Nobel Prize 2018-, co-founder of Raindance, HiFiBio...) and Jérôme Cros (cancer pathologist), who immediately detected the potential of the technology.

Our solution, covered by strong IP exclusively licensed to Minos by PSL University, allows scientists to uncover the full picture of cell diversity and dynamics, and to generate uniquely comprehensive datasets to fuel AI-driven drug discovery & development.

Minos has successfully demonstrated the power of its core technology and is now initiating the deployment of MinoSuite™ Pioneer, the Early Access Program (EAP) version of Minos solution.

[Back to Contents](#)




HHC medical

Presenter: Niels Clausen, CEO

HHC Medical has invented a novel approach to deliver nucleic acid-based therapies (NATs), based on Wireless ElectroPoration (WEP). Our WEP technology uses focused electromagnetic waves to temporarily manipulate cell membranes at a target site in the body. This enables highly localized uptake of NATs into cells regardless of cell type, overcoming the limitations and safety concerns of viral vectors and nanoparticles. This presents a unique opportunity to treat solid tumors with the extremely potent IL-2 compound. We combine an engineered pDNA with our delivery technology to get highly localized expression of IL-2 directly in the tumor - something no other delivery technology has been able to do. The IL-2 MoA is well-proven to treat many types of solid tumors. Our lead asset is targeting head and neck cancer, followed by assets targeting pancreatic cancer, and glioblastoma.

[Back to Contents](#)



Biotech Room 1 Pitches

Morning

Theme: More in drug development

Moderator: Hollie Vile, Optimum Strategic Communications



Presenter: Pedro Correa de Sampaio, CEO

Neobe is a preclinical startup on a mission to unlock the curative potential of existing cancer drugs. We are developing a synthetic biology platform to break down fibrotic barriers in solid tumors which prevent therapeutic efficacy.



Presenter: Thomas Kledal, CEO

Synklino, the Danish biotechnology company developing transformative therapies to treat chronic viral infections and eradicating latent viral reservoirs through targeting virus encoded membrane proteins

[Back to Contents](#)





Presenter: Enrique Tabares, Head of Development


MicroA is a pioneering pre-clinical stage company revolutionizing respiratory and lung disease therapy through its innovative polysaccharide platform technology. Our lead compound, MA001, addresses a critical unmet need, targeting exacerbations for over 400 million patients suffering from chronic pulmonary disease. Backed by robust expertise in industrial fermentation and drug development, MicroA is uniquely positioned to transform respiratory care and deliver breakthrough solutions that significantly enhance patient outcomes.



Presenter: Mark Bodmer, CEO

Nucleome is using breakthrough genomics technologies to discover first-in-class antibody therapeutics for inflammatory diseases. The approach is based solely on human disease genetics and biology. For the first time we can reveal molecular mechanisms of disease and select drug targets using human genetic variants in the non-coding genome that alter gene expression. Proprietary 3D genomics combines lab and machine learning technologies which can be applied to any set of disease-associated variants.

[Back to Contents](#)



Lead program NTP464 is an antibody that activates an inflammation checkpoint. NTP464 stimulates natural cellular processes of inflammation resolution, a new principle in the treatment of inflammation with huge potential patient benefit. Multiple further targets based on the genetics of inflammatory diseases are in discovery.

Nucleome is backed by a world-class syndicate of investors that includes M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson and Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital; and founding investor Oxford Science Enterprises.




Presenter: Jonathan Kwok, CEO

Cancer Research UK spinout from Oxford University, successfully bringing together people and science from UK, Europe, North America & Australia, to exploit leading-edge cancer immunology science in:

- * tumour specific antigen targeting
- * strong/durable vector delivery systems
- * cost effective biomanufacturing
- * clinical trial strategies to optimise for patient success

[Back to Contents](#)



On schedule to begin a game-changing phase I/IIa proof-of-concept trial Q2'25, to prevent or significantly delay recurrence for newly diagnosed patients streamed to first line therapy.

Winner of two prestigious Innovate UK technology awards (totalling £4m).


Seeking life science investor partners for Series A, and Pharma/Big Biotech collaborators with an interest in gaining access to the world's best tumour targeting pipeline.



Presenter: Carolyn Porter, CEO

Outrun Therapeutics is a preclinical biotech developing small molecule E3 ligase inhibitors to unlock the therapeutic potential of protein stabilisation for the treatment of cancer and other diseases.

[Back to Contents](#)



Biotech Room 2 Pitches

Morning

Theme: CNS - Novel approaches

Moderator: Noga Yerushalmi, M Ventures

ReSynapse Tx

Presenter: Dorit Cohen Carmon, Founder

ReSynapse Therapeutics: Redefining Mental Health Treatment with Precision Multi-Target Drugs

We're developing multi-target compounds for serotonin modulation to create fast-acting, long-lasting treatments for depression and anxiety. Our approach:

- Targets specific multi-CNS receptors
- Aims to overcome limitations of SSRIs and psychedelic-derived treatments
- Utilizes advanced AI-driven drug design

Recent achievements:

- Non-dilutive grant awarded for our novel "recipe" platform
- Positive KOL evaluation of feasibility and validation

Seeking seed funding for POC development and strategic partnerships to advance our mission.

[Back to Contents](#)





Presenter: Lovisa Sunesson, Director of Business Development


Vesper Bio is a private, VC-backed, clinical stage company with world-leading domain expertise in Vps10p domain receptors, developing a rich pipeline of first-in-class small molecule sortilin modulators for a number of critical unmet medical needs in the CNS space.



Presenter: Andreas Tremml, COO

Origenis is a drug discovery company developing a near clinical brain-penetrating CDK9 inhibitor

[Back to Contents](#)





Presenter: Robert Johnson, CEO

Kesmalea is developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules.

Kesmalea's SELFTAC® platform is a widely applicable solution to the "size problem" of Targeted Protein Degraders. We insert a reversible linker between the two main components of these large degraders, transforming them into small molecules that self-assemble into the bifunctional degrader at the appropriate location to fight disease. As small molecules, their oral bioavailability and ability to penetrate the central nervous system is much easier to achieve.

The SELFTAC platform was built on foundational scientific work by Harry Finch, PhD, the Company's Founder & CSO, a noted medicinal chemist with an extensive career in both cutting-edge start-ups and large pharma. The SELFTAC technology was the basis for Kesmalea's £25m Series A funding in 2022 co-led by Syncona Ltd and Oxford Science Enterprise.

Kesmalea's pipeline reflects the broad opportunity of TPD in prevalent chronic diseases, with drug discovery currently underway in oncology and CNS. We are pursuing both in-house development and collaborating with other companies with complimentary technologies and capabilities.

[Back to Contents](#)





Presenter: Henning Steinhagen, CEO

Lario Therapeutics Limited is a preclinical-stage drug discovery company based in Edinburgh (UK). Lario has been incorporated as a spinout from Epidarex Capital in Nov 2021 and is developing first-in-class precision medicines for epileptic and neurological disorders. Lario's pipeline is composed of genetically validated programs with a key focus on the development of novel therapies for severe pediatric syndromes. Both of these severe genetic disorders are characterised by treatment-resistant forms of epilepsy, profound developmental delay and movement difficulties. In addition to the disease-modifying focus on rare pediatric genetic syndromes, Lario's projects also target various drug-refractory forms of epilepsy as well as other neurological disorders including Parkinson's disease. Lario has recently received a \$6m award from MJFF and its leading projects are rapidly advancing towards the clinics.

[Back to Contents](#)





Presenter: Walden Bjørn-Yoshimoto, CEO

At Akasi Pharma, we are dedicated to developing safe and efficacious non-opioid therapeutics to treat peripheral neuropathic pain. Inspired by the fish-hunting marine cone snails, we have developed the most potent and selective activators of the somatostatin receptor 4, an intriguing new pain target that was recently clinically validated.

Our initial target indication is diabetic peripheral neuropathic pain (DPNP), a detrimental persistent pain condition with a life time incidence in diabetics of 50 %. DPNP has proven notoriously difficult to treat, with fewer than half of patients finding sufficient relief from current treatments. The dedicated team at Akasi Pharma is working to provide the best-in-class solutions for these patients.

[Back to Contents](#)



Technology Room Pitches

Afternoon

Theme: Novel tech solutions for Life Sciences

Moderator: Eva Haas, Optimum Strategic Communications



ASTRAVEUS

Presenter: Jeremie Laurent, CEO


Astraveus builds Benchtop Cell Factories that bring order of magnitude improvement to the scale and cost of cell and gene therapies manufacturing.



Presenter: Michael Lutz, CEO

iotaSciences is a leader in the rapidly evolving field of single-cell biology with fully automated modular patented platforms for single-cell isolation, cloning, and picking, as well as proven cell-line engineering experiences. We enable researchers to increase the speed and efficiency of cell biology research to accelerate new frontiers, helping them to get the most out of every cell and progress the therapies of the future, faster.

[Back to Contents](#)





Presenter: Rosie Dawaliby, Co-founder & CEO

G.CLIPS Biotech aims at Impact Healthcare by revolutionizing the discovery of new class of therapeutics based on our innovative platform.

We change paradigm on targets to discover, generate and validate conformation and pathology sensitive drug candidates.

We solve healthcare innovators' problems with our solutions:

- Unlock regulatory and deals issues for their drug candidate already in development


(Target validation, Target engagement, Mechanism of action, Target production for tox studies, Cell-free potency assay for CMC).

- Generate additional value and IP for optimization and selection of new drugs

Target identification, Secondary screening for efficacy, Evaluation of potential toxicity, Candidate profiling).

- Diversify their assets pipeline and create new IP (Target selection, Cell-free functional testing, Pathology-like primary screening, Target production for hit generation).

[Back to Contents](#)





Presenter: Cora Griffin, Head of Business Development


Curve's proprietary, Microcycle platform enables the enrichment of active molecules from libraries of Microcycles on the basis of biological function inside a live mammalian cell, and facilitates the discovery of drug candidates that can address high priority disease targets. Microcycles are a privileged molecular scaffold that occupy distinct chemical space; they are small, rigid, fold predictably, and have a defined pharmacophore. The amalgamation of these properties generates a Structure-Activity Relationship within each screen and provide a clear path to a cyclic peptide or small molecule drug.

The combination of functional in-cell screening and the unique structure of Microcycles enables the identification of transient, uncommon or allosteric sites on targets that would be invisible to conventional in vitro methods.

Using this platform, Curve is developing a strong pipeline, with a focus on cancer, immunology and inflammation.

The company has raised £45 Mn to date, including a £40 Mn Series A in January 2024. In 2022, the company signed a 5 target discovery collaboration with MSD.

[Back to Contents](#)






Presenter: Sam Whitehouse, CEO

LightOx is a UK life sciences company specialising in the development of light-activated therapeutics. Our lead drug candidate, LXD191 has been formulated into a topical gel designed to treat early-stage oral cancers and pre-cancerous lesions. This treatment involves applying the gel directly to the affected area and activating it with a specific wavelength of light, inducing targeted cell death while minimising damage to surrounding healthy tissues. Pre-clinical studies have shown promising results, and the company plans to initiate Phase I/IIa clinical trials in 2026.

LightOx's innovative approach aims to provide less invasive and more effective treatments for patients, particularly in the field of oral healthcare. By leveraging light-activated compounds, they seek to improve patient outcomes and reduce the side effects associated with traditional treatments like surgery or radiotherapy. Further to this, LightOx has developed a new drug compound LXD231, which targets bacterial cells in wound application. This drug has been shown to be effective against all the WHO ESKAPE pathogens, Gram positive and negative, and mycobacterium.

[Back to Contents](#)





Presenter: Troels Jordansen, CEO

We discover and develop life-saving treatments for patients with advanced liver disease at high risk of hospitalisation and death. Our treatments are designed either to prevent or treat rare or life-threatening liver diseases.

We have a diverse late-stage pipeline including two medical devices and two therapeutic medicines for acute and chronic use. Yaqrit is structured with four subsidiary companies to enable investment at the asset level or the parent company level.

[Back to Contents](#)



Biotech Room 1 Pitches

Afternoon

Theme: More in drug development

Moderator: Nadiya Ishnazarova, M Ventures



Presenter: René Jørgensen, Co-Founder & CEO


At Proxi Biotech our mission is to help patients escape the burden of bacterial re-infections. Our lead therapeutic candidate is targeting recurrent *Clostridium difficile* infections, which is a huge societal & economic burden.



Presenter: Bobby Zubis, Director Corporate Development

Resolution Therapeutics is a clinical stage biotechnology company pioneering Regenerative Macrophage Therapy in inflammatory and fibrotic diseases. Our flagship program focuses on developing engineered autologous macrophages for the treatment of end stage liver disease, an indication with a large and growing patient population with no available treatment other than liver transplantation. This transformative work is founded on the groundbreaking research of world-renowned macrophage cell therapy experts from the University of Edinburgh, Professors Stuart Forbes and John Campbell.

[Back to Contents](#)





Presenter: Jordan Abdi, Co-Founder & CEO


U-Ploid is a biotechnology company developing next-generation reproductive health therapeutics to address the global unmet need of age-related fertility decline. The Company's lead program is a first-in-class drug candidate, with promising preclinical activity against age-related damage in oocytes. Co-founded by leading scientists and industry experts, U-Ploid is pioneering innovative solutions to improve IVF outcomes and expand the window of reproductive opportunity. U-Ploid is committed to improving access to better reproductive health outcomes and envisions a future where anyone who wants to start a family, can.




Presenter: Mehdi Chelbi, CEO

We aim at saving patients' lives by developing first-in-class patented small molecules in oral administration pushing cancer cells to burn out through a unique mechanism of action. Our first clinical candidate BPR001-615 is the only selective BiP inhibitor in development.

[Back to Contents](#)



This treatment has been developed to treat BiP positive patients combining our broad-spectrum targeted therapy and a precision medicine approach based on a blood test to select BiP positive patients. BPR001-615, demonstrated in vivo efficacy proof of concept in several cancer indications associated with a very good tolerability profile. BPR001-615 is at 6 months from the Phase 1/2a in relapsing/refractory patients with gastro-intestinal cancers and has enormous potential as a new therapeutic solution to treat the 50% of BiP positive patients in monotherapy and in combination with standards of care from 1st lines of treatment.



Presenter: Niccolò Pengo, CSO

Swiss biotech company in the immunology and inflammation space (I&I). Our lead assets are in the allergy space (food and pollen), the fastest growing Type 2 immunology market with major unmet medical need.

We are currently raising our series B (USD 60M). 1/3 of the 60M series B has been already committed by current investors.

Phase 1 for our lead asset (MY006 for peanut allergy) is expected to start in Q4 2025.

Phase 1 for our lead asset (MY006 for peanut allergy) is expected to start in Q4 2025.

[Back to Contents](#)



With our lead asset (MY006 for peanut allergy), we expect to a) achieve 100% protection (vs 1/3 of treated patients not protected in the case of our competitors' therapies) ; b) significantly fewer injections/year (2 injections/year vs 12-24 injections/year), and c) rapid onset of immunity (days vs weeks/months).

Our competitors' therapies (desensitization, anti-IgE, and immunomodulatory therapies) – Palforzia and Xolair approved, others in the pipeline - fall short in terms of efficacy and patient compliance.



Presenter: Sebastian Honoré, CEO

Walther Therapeutics is pioneering innovative AAV-directed gene therapy specifically tailored to address rare genetic kidney diseases, initially targeting Lowe Syndrome and Dent Disease Type-2. These disorders severely impact kidney function, drastically reducing patient lifespan and quality of life, and impose significant emotional and financial burdens on affected families. Currently, available treatments are limited to symptom management and do not target the root genetic cause, underscoring a critical unmet medical need.

[Back to Contents](#)



Our proprietary gene therapy platform utilizes AAV vector technology uniquely engineered to target kidney-specific cells, particularly proximal tubule epithelial cells and the kidney stem cell niche. This approach optimizes therapeutic efficacy, minimizes systemic exposure, and utilizes clinically proven, minimally invasive urological procedures.

Leveraging validated kidney organoid models capable of accurately simulating numerous rare kidney disorders, our scalable platform offers extensive applicability to conditions affecting more than 300,000 patients globally. With strategic partnerships in place, including institutions such as the Telethon Institute of Genetics and Medicine (TIGEM), Walther Therapeutics is well-positioned to rapidly advance through regulatory processes and preclinical validation.

We are currently seeking €4 million in funding to achieve critical preclinical milestones and to position the company strategically for initiating first-in-human clinical trials.



Biotech Room 2 Pitches

Afternoon

Theme: New modalities and administration methods

Moderator: Stephen Adams, Optimum Strategic Communications




BIOARCHITECH

Presenter: Kevin Maskell, CEO/CSO & Founder

Bioarchitech mines the genomes of viruses to develop immunotherapy treatments aimed at improving the lives of cancer patients. A preclinical-stage company based in Oxford seeking Series-A investment and partnerships to advance two promising and differentiated assets into clinical studies for common and challenging cancers.

BA-V151, our lead candidate is an intravenously delivered virus expressing a proprietary nanobody. Designed to synergise with monoclonal antibody therapy through localised blockade of CD47 which promotes immunity and elimination of metastases in preclinical models. A Phase I clinical trial is planned to evaluate its potential as a neoadjuvant therapy for metastatic colorectal cancer.

[Back to Contents](#)





Presenter: Alistair Irvine, CEO

Scarlet Therapeutics is developing a unique platform that makes modified therapeutic red blood cells to potentially treat a wide range of diseases and was born out of more than a decade of research at the University of Bristol, and the NHSBT and its RESTORE study. Initially targeted at the rare metabolic diseases, *hyperammonemia* and *hyperoxaluria*, this approach could be used more broadly to target cancer and autoimmune diseases. Therapeutic red blood cells have many unique qualities, including pervasive reach throughout the body, a long active life and the ability to carry the active proteins within the cell, where they are shielded from the immune system.



Presenter: Thomas Sandal, CDO

Blue Cell Therapeutics (BCT) has developed a clinic ready, scalable, safe and long lasting allogeneic cell therapy for nerve regeneration and angiogenesis. Its lead product, BlueC-231 is in development for the treatment of severe Erectile Dysfunction (ED) with other indications under investigation.

[Back to Contents](#)



More than 85 million men are affected with ED worldwide, and their quality of life is significantly impacted. Depending on the underlying reason(s) for the ED the currently available treatment options are often ineffective, as well as they come with significant side effects and must be timed.


Our lead programme, BlueC-231, treats severe ED, such as post-prostatectomy, by addressing the root causes of poor blood flow and nerve damage. Preclinical in vitro and in vivo data has shown angiogenesis and endothelial cell and nerve cell regrowth superior to autologous cells, giving confidence for proposed phase 1/2a studies.

An early proof of concept study with a single dose of autologous adipose MSCs conducted at Odense University Hospital in Denmark demonstrated that 72% of the 11 men who had undergone prostatectomy and were continent but had no erectile function for over a year, regained their ability to have an erection and perform sexually at six months.

Blue Cell's therapy offers a scalable, safe and potentially curative solution, restoring erectile function for extended periods and spontaneity to sexual encounters.

To further the development and commercialization of our technology, we are actively exploring opportunities for partnership and funding.

To reach clinical validation in the phase 1/2 study described Blue Cell is looking to raise 39 million EUR





ReNewVax Ltd.

Presenter: Neil Murray, CEO

ReNewVax is a next generation vaccine company developing therapeutic vaccines targeting some of the world's most acute bacterial disease challenges.

The company's lead program RVX-001, is targeted at *Streptococcus pneumoniae* (also known as the pneumococcus). A major cause of global morbidity and mortality from pneumonia, septicaemia and meningitis, *Strep. Pneumoniae* is the third-leading cause of death from bacterial infection globally and the fourth-leading cause of deaths associated with Antimicrobial Resistance (AMR). This is despite the availability of pneumococcal vaccines since 1983, which have generated the largest global market for any vaccine (prepandemic) with annual sales of ca. \$10bn.

The limitations of existing products have led to the World Health Organisation (WHO) leading calls for a lower cost, universal vaccine to *S. pneumoniae*, that will provide coverage against all strains.

RVX-001 is the first universal vaccine to protect against this key pathogen.

[Back to Contents](#)





Presenter: Scott Quianoo, Business Developer

Cymab is a developer of novel therapeutics designed to fix several challenges with recombinant drugs and provide control of the immune system's regulatory mechanisms. The company offers novel therapies based on bispecific antibodies that allow the accumulation, modulation and targeting of endogenous cytokines already present in the patient's blood to the tumor site, enabling the therapists to accumulate, modulate, and target endogenous cytokines already present in the patient's own blood to the tumor site by activating the patient's immune system to fight the cancer.



Presenter: Gisela Lorente, CEO

Aptadel is a preclinical stage biotech company developing a platform of aptamer drug conjugates whose dual mechanism of action, antimetastatic effect and intracellular transport of different therapeutic agents, has the potential to be more effective and safer than the current SoC used in cancer management.

[Back to Contents](#)




Charity of the Year

Cure Parkinson's is here for the cure

- Parkinson's is the fastest growing neurological condition in the world.
- Since being founded in 2005, Cure Parkinson's has committed more than **£25m** of funding for Parkinson's research, into over **80** separate **research projects**



CURE
PARKINSON'S



Back to Contents




Delegations

BI | BiInnovation Institute

BiInnovation Institute's vision is to support world-class life science innovation that drives the development of new solutions by early-stage life science start-ups for the benefit of people and society. Our mission is to incubate world-class life science and catalyze the commercialization of new solutions through start-ups by using our knowledge, network, funding, and infrastructure.



[Back to Contents](#)



Delegations



We will create a better North East by connecting communities, giving people the skills to succeed and improving wellbeing for all. Collaborating with our partners we will make sure the North East is recognised as an outstanding place to live, work, visit and invest.



cpi




LANT MEDICAL



National Innovation
Centre **Ageing**

LIGHTOX[®]


[Back to Contents](#)



ATTENDING INVESTORS


1004 Venture Partners	Calculus Capital	Forbion
4BIO Capital	Cancer Research Horizons, Ventures	Foresight Group
Albion VC	CBG	General Inception
Angelini Ventures	Cell and Gene Therapy Catapult	GL Capital
ARCH Venture Partners	Claret Capital Partners	Global Brain
Avant Bio	CPI Enterprises	GSK
AXA Investment Managers	Danaher Ventures	H Tree Capital
Baselaunch	Delin Ventures	Healthcare Royalty
Bioscience Equity Partners Group	DGB Ventures	Ignite Capital Partners
Biovision Ventures	Eli Lilly and Company	Indaco Venture Partners
BlackRock	Epidarex	Intermediate Capital Group (ICG)
Bluebirds Capital	Eppendorf Group SE & Co. KG	Inveready Asset Management
Brandon Capital Partners	Evolutia Venture Partners	IPF Partners
British Business Bank	First Spark Ventures	ITOCHU Europe PLC

[Back to Contents](#)



Jeito Capital	Novalis II General Partner BV	SPRIM Global Investments
JJDC	Octopus Ventures	SR One
Keles	OrbiMed	SV Health Investors
Kerna Ventures	Oxford Science Enterprises	Syncona
Kineo Finance	Panakes Partners	TechBio
Lunar Ventures	Parkwalk Advisers	The Pioneer Group
M Ventures	Peppermint Venture Partners	Type One Ventures
Macmillan	Pioneer Group	UCB Ventures
MAKR Venture Fund	Rosetta Capital	Vesalius Biocapital Partners
Medicines Discovery Ventures	RYSE Asset Management	XGEN Venture
Meltwind	Segulah Medical Acceleration	Zinc Ventures
Momentum Biotech	Seventure	
Monograph	Sofinnova Partners	
New Science Fund	SOSV	
NLC Health Ventures	Sound Bioventures	
Nodenza Venture Partners		
Norn Ventures		

[Back to Contents](#)




ATTENDING COMPANIES AND ORGANISATIONS

2N Pharma ApS	BBI Cambridge	Blue Cell
AION Labs	Beech Biotech	Therapeutics
Akasi Pharma	BerGen Bio	Bristows
Alder Therapeutics	BGF	Business Region Göteborg
Altasciences	BGV	Business Sweden
Animal Health EU & UK	BII	Calliditas Therapeutics
Anocca	Bioarchitech	Cambridge Rare Disease Network
Another Day Pharma	BioCentury	Carbogen Amcis
Apex Molecular Ltd	Bioline, Meridian	Catalent
Aptadel	Bioscience	CatSci Holdings
Therapeutics	BioPartner UK	Cbio A/S
Ardena	Biotechnology	Citeline
Argentum	Business Institute	Clarivate
Consultants	BioWorld	CMS
Astellas Pharma	BiPER Therapeutics	Collaborative Drug Discovery
Astraveus	Bloomberg	
Axplora		


Convergence	Freeths	LEO Foundation
Partners	Freya Biosciences	LightOx
Cooley	G.CLIPS biotech	Lonza
CuraCell	GenScript	LoQus23
Cure Parkinson's	Harmonic	Therapeutics
Curve Therapeutics	Discovery	Mabylon AG
Cymab	HHC Medical	Manchester University NHS Foundation Trust
DLRC	In Vivo	Marett Consulting
DNA Electronics	Incipiam Pharma	MedCity UK
DoMore	Infinetopes	Medicon Valley Alliance
Diagnostics	Precision	Merck Healthcare
Duke-NUS Medical School	Immunomics	Merck KGaA
Econic Biosciences	InsideReg Ltd	MicroA
EIP	iotaSciences Ltd.	Microverse Studios
Embassy of Israel	Ipca Onyx Scientific	Minos Biosciences
Evariste	IQVIA Biotech	MQ Mental Health Research
Ezenze	Just-Evotec	mycoBiologics Ltd
Ferring	Biologics	Navira
Pharmaceuticals	Kesmalea	
FreeMind Group	Therapeutics Ltd	
	Lario Therapeutics	

[Back to Contents](#)



Neobe	Pictura Bio	Senglobal
Nouscom	Plague Prevention Strategies	Communications
Nucleome Therapeutics	Plantform Corporation	Serenatis Bio
o2h Ventures Ltd	Polyceutix	SGS Quay Pharmaceuticals
Oncoinvent	Porsolt	Simmons & Simmons
Onconox Inc.	Precirix	StemSight
OPIS srl	Proxi Biotech	Stephenson Harwood
Oppilotech Ltd	Quotient Sciences	Sterling Pharma Solutions
Optimum Strategic Communications	Raymond James	Stevenson Search Partners
Origenis	ReNewVax	Sue Herbert
Outrun Therapeutics	Resolution Therapeutics	Synklino
Oxford Vacmedix	ReSynapse Therapeutics	Synuca
Pephexia Therapeutics ApS	Reuters	Tenaces Biosciences
Pharma Holdings	Roald Dahl's Marvellous Children's Charity	The Francis Crick Institute
Pharmacelera	Scancell	The RSA Group
Pharmaceutical Technology	Scarlet Therapeutics	UK Government Department for Business and Trade
PharmEnable Therapeutics	Scendea	

[Back to Contents](#)



University of Florida

U-Ploid

Biotechnologies

UPyTher BV

UrkWorks

Valink Therapeutics

Vectiopep

Veranova

Vesper Bio

Vox.Bio

Walther
Therapeutics


WuXi AppTec

WuXi Biologics

Xterna

Yaqrit

[Back to Contents](#)



ANGLO NORDIC

